Gordan, John D. http://orcid.org/0000-0001-8997-5725
Keenan, Bridget P.
Lim, Huat Chye
Yarchoan, Mark
Kelley, R. Katie
Funding for this research was provided by:
Burroughs Wellcome Fund
Article History
Accepted: 5 June 2023
First Online: 4 July 2023
Declarations
:
: Dr. Gordan is supported by a Burroughs Wellcome Fund Career Award.
: Dr. Gordan and Dr. Lim declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. Dr. Keenan is a member of the consulting/advisory board of Regeneron and has received research funding from Partner Therapeutics and travel funds from Roche/Genentech. Dr. Yarchoan has received research support from Bristol-Myers Squibb, Incyte and Genentech and honoraria from Genentech, Exelixis, Eisai, AstraZeneca, Replimune, and Hepion. Dr. Yarchoan is a co-founder of Adventris Pharmaceuticals and holds equity. Dr. Kelley has received research funding from Agios, Astra Zeneca, Bayer, BMS, Eli Lilly, EMD Serono, Exelixis, Genentech/Roche, Loxo Oncology, Merck, Novartis, Partner Therapeutics, QED, Relay Therapeutics, Surface Oncology, and Taiho, as well as consulting/advisory fees from Agios, Astra Zeneca, BMS, Exelixis, Ipsen, Merck, Compass, Exact Sciences, Kinnate, Regeneron, and Tyra Therapeutics. She has received travel support from: Astra Zeneca and Merck.
: All authors contributed to the conceptualization of the review, manuscript preparation, and manuscript review.
: No datasets were generated or analyzed during the current study.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.